320 related articles for article (PubMed ID: 37430086)
1. Where should siRNAs go: applicable organs for siRNA drugs.
Ahn I; Kang CS; Han J
Exp Mol Med; 2023 Jul; 55(7):1283-1292. PubMed ID: 37430086
[TBL] [Abstract][Full Text] [Related]
2. Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage.
Guo F; Li Y; Yu W; Fu Y; Zhang J; Cao H
Mol Pharm; 2024 May; 21(5):2081-2096. PubMed ID: 38630656
[TBL] [Abstract][Full Text] [Related]
3. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
5. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
6. Journey of siRNA: Clinical Developments and Targeted Delivery.
Nikam RR; Gore KR
Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.
Zhang J; Chen B; Gan C; Sun H; Zhang J; Feng L
Int J Nanomedicine; 2023; 18():7605-7635. PubMed ID: 38106451
[TBL] [Abstract][Full Text] [Related]
8. Current progress of siRNA/shRNA therapeutics in clinical trials.
Burnett JC; Rossi JJ; Tiemann K
Biotechnol J; 2011 Sep; 6(9):1130-46. PubMed ID: 21744502
[TBL] [Abstract][Full Text] [Related]
9. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
[TBL] [Abstract][Full Text] [Related]
10. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
Aigner A
J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
[TBL] [Abstract][Full Text] [Related]
11. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
13. Progress in RNAi-based antiviral therapeutics.
Zhou J; Rossi JJ
Methods Mol Biol; 2011; 721():67-75. PubMed ID: 21431679
[TBL] [Abstract][Full Text] [Related]
14. The growth of siRNA-based therapeutics: Updated clinical studies.
Zhang MM; Bahal R; Rasmussen TP; Manautou JE; Zhong XB
Biochem Pharmacol; 2021 Jul; 189():114432. PubMed ID: 33513339
[TBL] [Abstract][Full Text] [Related]
15. Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
Marinho HS; Marcelino P; Soares H; Corvo ML
Curr Pharm Des; 2018; 24(23):2692-2700. PubMed ID: 30084326
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
Jing X; Arya V; Reynolds KS; Rogers H
Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
[TBL] [Abstract][Full Text] [Related]
17. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
Aigner A
Appl Microbiol Biotechnol; 2007 Aug; 76(1):9-21. PubMed ID: 17457539
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
19. Structural Modifications of siRNA Improve Its Performance In Vivo.
Chernikov IV; Ponomareva UA; Chernolovskaya EL
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674473
[TBL] [Abstract][Full Text] [Related]
20. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
